Cue Biopharma (CUE) Earnings Analysis

Cue Biopharma (CUE) next reports earnings on 2026-08-18, consensus EPS -1.69 USD. Last quarter (2026-05-14) it beat with EPS -1.08 USD vs -3.3 USD est (+67.3%). It has beaten estimates in 5/6 recent quarters (83%). Trailing P/E -6.20.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does CUE next report earnings?

Next earnings date2026-08-18
Consensus EPS estimate-1.69 USD
Revenue estimate0.00B

CUE earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-14-1.08 USD-3.3 USD+67.3%Beat
2026-03-160.3 USD-2.7 USD+111.1%Beat
2025-05-12-0.17 USD-0.14 USD-21.4%Miss
2025-03-31-0.13 USD-0.16 USD+18.8%Beat
2024-11-14-0.17 USD-0.2 USD+15%Beat
2024-08-18-0.2 USD-0.29 USD+31%Beat

Beat rate: 5/6 (83%) over reported quarters with consensus data.

CUE valuation and analyst view

Trailing P/E-6.20
Trailing EPS-4.06095 USD
Price / book7.61
Dividend yield0.00%
Market cap0.09B
Analyst consensusBuy (9 buy / 0 hold / 0 sell)

Related research pages

Frequently asked questions

When is Cue Biopharma (CUE)'s next earnings date?

Cue Biopharma is next scheduled to report on 2026-08-18, with a consensus EPS estimate of -1.69 USD and revenue estimate of 0.00B.

Did CUE beat earnings last quarter?

In its 2026-05-14 report, CUE posted EPS of -1.08 USD versus a -3.3 USD estimate — a beat of 67.3%.

What is CUE's earnings track record?

Over the last 6 reported quarters with consensus data, CUE beat estimates 5 times (83%).

What is CUE's current P/E ratio and EPS?

CUE trades at a trailing P/E of -6.20 on trailing EPS of -4.060951506127725 USD.

What do analysts rate CUE?

Analyst consensus is "Buy" across 9 ratings (0 strong buy, 9 buy, 0 hold, 0 sell, 0 strong sell).